LDS/Medical Tests/Bupropion, Urine

Bupropion, Urine

Bupropion is a member of the class of drugs known as antidepressants. Use of antidepressants is one of the primary ways to treat clinical depression. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorders, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. Bupropion blocks the reuptake of norepinephrine and dopamine, which is why this particular drug is useful in treating attention deficit disorders and is a powerful aid to help people stop smoking. Bupropion is a member of the second generation of antidepressants.

Most antidepressants are metabolized by the cytochrome P450 system and many of the metabolites are biologically active. Bupropion is metabolized to hydroxybupropion, which is also biologically active. The half-lives of antidepressant drugs are quite variable. The half-life of bupropion is between 8-24 hours (average of 14). Many of the therapeutic ranges for these drugs have not been established or there is non-consensus.

The effects associated with bupropion abuse include hallucinations, headaches, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.

Bupropion is one of the most frequently encountered drugs of abuse due to the large majority of the population that is taking them, the frequency with which these drugs are prescribed, and their high potential for serious side effects.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay (IA) test indicates only the presence of primary amines and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic concentrations in blood: 50-100 ng/mL

Toxic concentration: > 300 ng/mL

Fatal concentration: variable

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, whether it is a qualitative method such as IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS). The main method of quantification is via LC/MS. This particular method of analysis can be used to detect bupropion. Bupropion can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step is often used to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3 hours
  • Refrigeration: 14 days
  • Frozen: 14 days
Pharmacogenetic testing such as genotyping for *CYP2B6* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
  • Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.